EP1148885A4 - Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo - Google Patents

Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo

Info

Publication number
EP1148885A4
EP1148885A4 EP00907132A EP00907132A EP1148885A4 EP 1148885 A4 EP1148885 A4 EP 1148885A4 EP 00907132 A EP00907132 A EP 00907132A EP 00907132 A EP00907132 A EP 00907132A EP 1148885 A4 EP1148885 A4 EP 1148885A4
Authority
EP
European Patent Office
Prior art keywords
efficacy
vivo
electrically
dna vaccine
vaccine immunity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00907132A
Other languages
German (de)
French (fr)
Other versions
EP1148885A1 (en
Inventor
Mark Selby
Cheryl Goldbeck
Terry Pertile
Robert Walsh
Margaret A Liu
Jeffery Ulmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
eMed Corp
Original Assignee
Chiron Corp
eMed Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp, eMed Corp filed Critical Chiron Corp
Publication of EP1148885A1 publication Critical patent/EP1148885A1/en
Publication of EP1148885A4 publication Critical patent/EP1148885A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0412—Specially adapted for transcutaneous electroporation, e.g. including drug reservoirs
    • A61N1/0416—Anode and cathode
    • A61N1/0424—Shape of the electrode
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0432—Anode and cathode
    • A61N1/044—Shape of the electrode
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A61N1/303—Constructional details
    • A61N1/306—Arrangements where at least part of the apparatus is introduced into the body
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP00907132A 1999-02-08 2000-02-07 Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo Withdrawn EP1148885A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11899699P 1999-02-08 1999-02-08
US118996P 1999-02-08
US12918999P 1999-04-14 1999-04-14
US129189P 1999-04-14
PCT/US2000/002831 WO2000045823A1 (en) 1999-02-08 2000-02-07 Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo

Publications (2)

Publication Number Publication Date
EP1148885A1 EP1148885A1 (en) 2001-10-31
EP1148885A4 true EP1148885A4 (en) 2002-05-08

Family

ID=26816956

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00907132A Withdrawn EP1148885A4 (en) 1999-02-08 2000-02-07 Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo

Country Status (4)

Country Link
EP (1) EP1148885A4 (en)
AU (1) AU2868200A (en)
CA (1) CA2361601A1 (en)
WO (1) WO2000045823A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US6562346B1 (en) 1999-10-27 2003-05-13 Chiron Corporation Activation of HCV-specific T cells
AU2002360648B2 (en) * 2001-12-14 2009-01-08 Genetronics, Inc. Methods for particle-assisted polynucleotide immunization using a pulsed electric field
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
PT1480720T (en) * 2002-03-07 2018-11-23 Inovio Pharmaceuticals Inc Electrode assembly for constant-current electroporation
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
WO2006055729A1 (en) * 2004-11-16 2006-05-26 Transcutaneous Technologies Inc. Iontophoretic device and method for administering immune response-enhancing agents and compositions
EP2816118B1 (en) 2005-05-31 2018-10-17 The Regents of the University of Colorado, a body corporate Methods for delivering genes
WO2007081447A2 (en) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
WO2008063555A2 (en) * 2006-11-17 2008-05-29 Genetronics, Inc. Methods of enhancing immune response using electroporation-assisted vaccination and boosting
WO2008089144A2 (en) * 2007-01-12 2008-07-24 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Improved dna vaccination protocols
EP2185195A2 (en) 2007-08-16 2010-05-19 Tripep Ab Immunogen platform
AU2009210624A1 (en) * 2008-01-11 2009-08-13 Vgx Pharmaceuticals, Inc. Novel vaccines against multiple subtypes of dengue virus
US9428565B2 (en) 2011-01-31 2016-08-30 The General Hospital Corporation Treatment and bioluminescent visualization using multimodal TRAIL molecules
EP2890720B1 (en) 2012-08-30 2019-07-17 The General Hospital Corporation Compositions and methods for treating cancer
CN110237270A (en) 2013-03-15 2019-09-17 洛马林达大学 The treatment of autoimmune disease
AU2014268603B2 (en) 2013-05-21 2018-03-22 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
US20180112006A1 (en) 2015-04-17 2018-04-26 The General Hospital Corporation Agents, systems and methods for treating cancer
US20220054827A1 (en) 2018-12-13 2022-02-24 Newsouth Innovations Pty Limited Method and system for controlling molecular electrotransfer

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039531A1 (en) * 1995-06-06 1996-12-12 Massachusetts Institute Of Technology Delivery of nucleotides into organisms by electroporation
WO1998043702A2 (en) * 1997-04-03 1998-10-08 Iacob Mathiesen Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
WO1999001175A1 (en) * 1997-06-30 1999-01-14 Rhone-Poulenc Rorer S.A. Device for optimized electrotransfer of nucleic acid vectors to tissues in vivo
WO1999001157A1 (en) * 1997-06-30 1999-01-14 Rhone-Poulenc Rorer S.A. Improved method for transferring nucleic acid into multicelled eukaryotic organism cells and combination therefor
WO1999004850A1 (en) * 1997-07-22 1999-02-04 Emed Corporation Needle for iontophoretic delivery of agent
WO1999036563A1 (en) * 1998-01-14 1999-07-22 Emed Corporation Electrically mediated cellular expression

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2087166T3 (en) * 1990-01-15 1996-07-16 Cino Rossi IONTOFORESIS DEVICE.
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5830877A (en) * 1993-08-26 1998-11-03 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
US5786464C1 (en) * 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039531A1 (en) * 1995-06-06 1996-12-12 Massachusetts Institute Of Technology Delivery of nucleotides into organisms by electroporation
WO1998043702A2 (en) * 1997-04-03 1998-10-08 Iacob Mathiesen Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
WO1999001175A1 (en) * 1997-06-30 1999-01-14 Rhone-Poulenc Rorer S.A. Device for optimized electrotransfer of nucleic acid vectors to tissues in vivo
WO1999001157A1 (en) * 1997-06-30 1999-01-14 Rhone-Poulenc Rorer S.A. Improved method for transferring nucleic acid into multicelled eukaryotic organism cells and combination therefor
WO1999004850A1 (en) * 1997-07-22 1999-02-04 Emed Corporation Needle for iontophoretic delivery of agent
WO1999036563A1 (en) * 1998-01-14 1999-07-22 Emed Corporation Electrically mediated cellular expression

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ABE ET AL: "A novel gene transfer method in vivo: The pulse electric field gene transfer (PEFGT)", GENE THERAPY, vol. 2, no. 9, November 1995 (1995-11-01), pages 694, XP001056944 *
BANGA AJAY K ET AL: "Iontophoresis and electroporation: Comparisons and contrasts.", INTERNATIONAL JOURNAL OF PHARMACEUTICS (AMSTERDAM), vol. 179, no. 1, 1 March 1999 (1999-03-01), pages 1 - 19, XP002192323, ISSN: 0378-5173 *
MASAYUKI NOMURA ET AL: "IN VIVO INDUCTION OF CYTOTOXIC T LYMPHOCYTES SPECIFIC FOR A SINGLE EPITOPE INTRODUCED INTO AN UNRELATED MOLECULE", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 193, 1996, pages 41 - 49, XP002928836, ISSN: 0022-1759 *
See also references of WO0045823A1 *
VANBEVER R ET AL: "IN VIVO EFFICACY AND SAFETY OF SKIN ELECTROPORATION", ADVANCED DRUG DELIVERY REVIEWS, AMSTERDAM, NL, vol. 35, no. 1, 1999, pages 77 - 78, XP001057033, ISSN: 0169-409X *

Also Published As

Publication number Publication date
CA2361601A1 (en) 2000-08-10
AU2868200A (en) 2000-08-25
EP1148885A1 (en) 2001-10-31
WO2000045823A9 (en) 2001-10-11
WO2000045823A1 (en) 2000-08-10

Similar Documents

Publication Publication Date Title
EP1148885A4 (en) Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo
AU1166502A (en) Human ect2 and methods of use
EP1487538A4 (en) Visual prosthesis including enhanced receiving and stimulating portion
IL143379A0 (en) ANTISENSE OLIGONUCLEOTIDE AGAINST HUMAN AChE AND USES THEREOF
EP1112091A4 (en) Rapid cryobaric sterilization and vaccine preparation
EP1421185A4 (en) Rapid cryobaric sterilization and vaccine preparation
HK1047242A1 (en) Physical strength enhancing agents and glycogen accumulation promoting agents
IL144845A0 (en) Vaccines and gene therapy compositions and methods of making and using the same
HK1042504A1 (en) Human cervical cancer 1 protooncogene and protein encoded therein
EP1161451A4 (en) Human endokine alpha and methods of use
AU4319001A (en) Microcompetiton and human disease
EP1317271A4 (en) Therapeutic and cosmetic uses of heparanases
EP1173189A4 (en) Asialocytokines and treatment of liver disease
EP1210111A4 (en) Gamma-herpesvirus dna and methods of use
GB9903919D0 (en) Aminophenols and their therapeutic use
IL146940A0 (en) Novel calpains and their use
HK1050026A1 (en) DNA CODING FOR β - TUBULIN AND USE THEREOF
IL150525A0 (en) 2-carboxamide-benzimidazoles useful in the treatment and prevention of isochemic reperfusion injury
EP1167527A4 (en) Processed human chemokines PHC-1 and PHC-2
GB9905300D0 (en) Therapy and use of agents in therapy
GB0015371D0 (en) Tumour-cell specific gene expression and its use in cancer therapy
IL146727A0 (en) Spliceosome protein and its use
GB0022210D0 (en) Treatment of infection in animals
GB0012401D0 (en) Treatment of infection in animals
GB9905307D0 (en) Therapy and use of compounds in therapy

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010906

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20020327

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20030930

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040211